Process Harmonization Assessments for Technology Transfer - A process harmonization assessment can aid in smooth technology transfer by comparing data across equipment and sites. - BioPharm

ADVERTISEMENT

Process Harmonization Assessments for Technology Transfer
A process harmonization assessment can aid in smooth technology transfer by comparing data across equipment and sites.


BioPharm International Supplements


Raw Materials

Transferring a process to a new facility typically will require a different set of preferred vendors for raw materials. If the raw materials have been registered, the sourcing of new raw materials must meet the registered specifications of the original supplier. If the raw materials are not registered, a side-by-side assessment should be done to ensure comparable quality. If comparable raw materials are not available, Design of Experiments with the new raw materials should be performed to assess the impact on the process. Depending on the number of raw materials, this section may be incorporated into a separate document to facilitate review and approval.

Conclusion

A process harmonization assessment (PHA) is a useful tool to compare various equipment sets proposed to manufacture a single product. PHA compares the process flow, primary process parameters, equipment sets, and raw materials between the two sites involved in technology transfer. Any technology transfer can benefit from the methodology of PHA. Node-to-node transfers benefit the most from the high level of detail contained in a PHA document. Technology transfers in early development can benefit from the documentation of the important parameters and initiate the development of these documents for future transfers. Technical resources at both the sending site and receiving site are involved to enhance the communication and technical expertise of both sites.

Andrew W. Rockabrand is an associate senior consultant engineer in Indianapolis API Engineering Servces at Eli Lilly and Co., Indianapolis, IN, 317.433.0545,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here